Methods for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women

Abstract

This invention relates to a method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, or to a method for treatment or prevention of symptoms related to said atrophy, said method comprising administering to the woman an effective amount of the compound of formula (I) or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.

1 . A method for inhibition of skin atrophy, or epithelial or mucosal atrophy in women, said method comprising administering to the woman an effective amount of the compound of formula (I)  
     
       
         
         
             
             
         
       
     
     or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.  
   
   
       2 . The method according to  claim 1  wherein compound (I) is ospemifene.  
   
   
       3 . The method according to  claim 1  wherein the atrophy is urogenital atrophy.  
   
   
       4 . The method according to  claim 2  wherein the atrophy is urogenital atrophy.  
   
   
       5 . A method for treatment or prevention of symptoms related to skin atrophy, or to epithelial or mucosal atrophy in women, said method comprising administering to the woman an effective amount of the compound of formula (I)  
     
       
         
         
             
             
         
       
     
     or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof.  
   
   
       6 . The method according to  claim 5  wherein compound (I) is ospemifene.  
   
   
       7 . The method according to  claim 5  wherein the atrophy is urogenital atrophy.  
   
   
       8 . The method according to  claim 7  wherein the symptoms are vaginal symptoms.  
   
   
       9 . The method according to  claim 8  wherein the vaginal symptoms are irritation, itching, burning, maladorous discharge, infection, dyspareunia, leukorrhea, vulvar pruritus, feeling of pressure, postcoital bleeding, vaginal dryness and difficulty in sexual arousal.  
   
   
       10 . The method according to  claim 1  wherein compound (I), its isomer, salt or ester is administered orally, topically, transdermally, intravaginally or subcutaneously.  
   
   
       11 . The method according to  claim 5  wherein compound (I), its isomer, salt or ester is administered orally, topically, transdermally, intravaginally or subcutaneously.  
   
   
       12 . The method according to  claim 7  wherein the symptoms are urinary symptoms.